Skip to main content
BioSenic SA logo

BioSenic SA — Investor Relations & Filings

Ticker · BIOS ISIN · BE0974280126 LEI · 549300HFIIMTOP1DFR76 BR Professional, scientific and technical activities
Open in API
Filings indexed 968 across all filing types
Latest filing 2023-05-15 AGM Information
Country BE Belgium
Listing BR BIOS

About BioSenic SA

http://www.biosenic.com/

BioSenic SA is a biotechnology company focused on developing innovative treatments for autoimmune diseases, inflammatory conditions, and bone disorders. The company's core activities are centered on two main technology platforms: one based on arsenic trioxide (ATO) for its immunomodulatory properties, and another involving allogeneic cell therapy for tissue repair and regeneration. BioSenic's objective is to address significant unmet medical needs in the fields of regenerative and immune medicine by advancing its clinical assets through development.

Recent filings

Filing Released Lang Actions
01_BioSenic_convening notice AGM 2023_FR_vfinal.pdf
AGM Information Classification · 100% confidence The document is explicitly titled 'CONVOCATION À L'ASSEMBLÉE GÉNÉRALE ORDINAIRE' (Notice of Ordinary General Meeting) and details the date (14 JUIN 2023), the agenda (ORDRE DU JOUR), and procedures for shareholder participation, voting, and proxy submission. This content directly relates to the materials distributed for an Annual General Meeting (AGM). Therefore, the appropriate classification is AGM Information (AGM-R).
2023-05-15 French
BIOS_PR_2023-05-04_Biomarker_cGvHD_EN_vfinal.pdf
Regulatory Filings Classification · 95% confidence The document is explicitly labeled as a 'PRESS RELEASE – INSIDE INFORMATION' dated May 4th, 2023. It announces a specific corporate action: the submission of a key patent related to their cGvHD diagnostic method and the potential financial impact. This type of announcement, detailing significant, non-financial operational news (like IP filings or clinical trial updates) released via a press release, fits best under the general 'Regulatory Filings' category (RNS) or potentially an 'Investor Presentation' (IP) if it were a slide deck, but since it's a news announcement about a specific event, RNS is the most appropriate general regulatory disclosure category when a more specific category like 'IP' or 'LTR' is not available. Given the options, RNS serves as the best fit for a general, material, non-periodic corporate announcement that isn't a financial result (ER/IR) or a management change (MANG). It is not a full report (10-K, IR) nor a proxy/dividend notice.
2023-05-04 English
BIOS_PR_2023-05-04_Biomarker_cGvHD_FR_vfinal.pdf
Investor Presentation Classification · 95% confidence The document is explicitly titled "COMMUNIQUÉ DE PRESSE – INFORMATIN PRIVILEGIEE" (Press Release – Privileged Information) and is dated 04/05/2023. It announces a specific corporate action: the filing of an international patent related to biomarker identification for cGvHD. This type of announcement, detailing scientific/IP developments and potential market impact, is characteristic of a general corporate press release. Since the document is a direct announcement of a significant event (patent filing) rather than a comprehensive periodic report (like 10-K or IR), and it doesn't fit neatly into specific categories like Director's Dealing (DIRS), Dividend Notice (DIV), or Earnings Release (ER), the most appropriate classification is the general regulatory announcement fallback category, RNS (Regulatory Filings). The length (14,913 chars) is substantial, but the content is a direct announcement, not a full regulatory filing form.
2023-05-04 French
BIOSENIC ESEF_ENG.pdf
Annual Report Classification · 100% confidence The document is explicitly titled 'FINANCIAL REPORT 2022' and contains a comprehensive table of contents covering the Board of Directors' report, corporate governance, remuneration, and full consolidated financial statements (IFRS) for the fiscal year ending 31 December 2022. It includes detailed notes to the financial statements and auditor information, which are characteristic of a full Annual Report (10-K equivalent). FY 2022
2023-04-27 English
BIOSENIC ESEF_FR.pdf
Annual Report Classification · 100% confidence The document is explicitly titled 'RAPPORT FINANCIER 2022' (Financial Report 2022) for BIOSENIC SA. It contains a comprehensive table of contents covering the Board of Directors' report, financial statements (IFRS), notes to the financial statements, governance information, and audit reports for the fiscal year ending December 31, 2022. This matches the definition of an Annual Report (10-K equivalent for international entities). FY 2022
2023-04-27 French
549300HFIIMTOP1DFR76-2022-12-31-en.xhtml
Annual Report Classification · 100% confidence The document is explicitly titled 'FINANCIAL REPORT 2022' and contains comprehensive sections including a letter to shareholders, business overview, corporate governance, detailed consolidated financial statements (IFRS), notes to the financial statements, and a statutory auditor's report. It covers the full fiscal year ending 31 December 2022. This structure matches the definition of an Annual Report (10-K). FY 2022
2023-04-27 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.